Newport Medical Instruments Inc. has been acquired by Covidien plc
Newport Medical Instruments, Inc. (Newport), a manufacturer of ventilators for the portable, home care and critical care markets, has been acquired by Covidien plc. for US$108 million.
Newport is a physician-led company, focused on the design and manufacture of dependable ventilators that are affordable for caregivers worldwide.
Covidien plc. is a leading global provider of healthcare products and recognized innovator in patient monitoring and respiratory care devices. Covidien creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence.
Oaklins' team in Los Angeles was engaged by the shareholders of Newport to pursue a sale of the business.
Talk to the deal team
Adam Abramowitz
Oaklins Intrepid
Eduard Bagdasarian
Oaklins Intrepid
Steven Davis
Oaklins Intrepid
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreSLT has been acquired by Indutrade
SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.
Learn more